Form 4: TScan Therapeutics Director Barbara Klencke Increases Stake in Company

Director Barbara Klencke increased her holdings in TScan Therapeutics through open market purchases.

Summary

• Barbara Klencke, a director of TScan Therapeutics, has reported changes in her beneficial ownership of the company's stock.
• On August 23, 2024, she purchased 5,000 shares of Voting Common Stock at $5.69 per share.
• On August 26, 2024, she purchased another 5,000 shares of Voting Common Stock at $5.53 per share.
• Following these transactions, Ms. Klencke directly owns 40,000 shares and indirectly owns 25,000 shares through a trust.
• The indirect ownership is held by the Klencke Huestis Trust, where Ms. Klencke serves as co-trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a relatively small transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. Purchases are generally viewed more favorably than sales.

Stakeholder Impact

• The increased stake by a director could positively influence shareholder sentiment.

Key Dates